Background In classic Hodgkin lymphoma (cHL), identifying high-risk patients is crucial for tailored treatment. Clinical risk factors are useful, but there is room for improvement. Although many diagnostic tissue-based biomarkers have been described to correlate with prognosis, none have achieved the accuracy to be inc...
Rodrigo Martinez Alcala, L. Visser, C. Fortpied et al.· PLoS ONE· 0 citations
It is demonstrated that ctDNA could potentially be used for prognostication and disease monitoring in PTLD, outperforming PET/CT in 8 cases, indicating that ctDNA monitoring can complement PET/CT to guide early escalation to chemotherapy in high-risk patients, though larger cohorts are needed to validate these findings...
Y. Zhong, Nick Veltmaat, Filipe Montes de Jesus et al.· Blood Advances· 0 citations
This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study was executed in five hospitals in the Netherlands and Belgium to evaluate the safety and determine the recommended phase 2 dose of GLPG5101.
M. Kersten, M. Kuipers, P. Mutsaers et al.· The Lancet Haematology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.